Gene Therapy Design Using AAV Viral Vectors | BHU Lecture

Added:

Limitations of AAV Vectors and the Shift to Non-Viral Delivery Systems

While Adeno-Associated Virus (AAV) vectors are currently the gold standard for gene delivery, they possess significant limitations that have led many researchers to advocate for non-viral alternatives. Key criticisms of AAVs include high rates of pre-existing immunity in the human population (which excludes many patients from treatment), severe immune-mediated toxicity at high doses, and the inability to re-dose patients due to neutralizing antibodies developed after the first treatment. Additionally, AAVs have a strict cargo limit of approximately 4.7 kilobases, making them unsuitable for larger therapeutic genes. Consequently, a strong counter-perspective champions non-viral delivery platforms, particularly lipid nanoparticles (LNPs) and polymeric vectors. These synthetic alternatives do not trigger the same severe immune responses, allow for repeated dosing, have significantly larger payload capacities, and are much easier to manufacture at scale. This school of thought argues that the long-term future of gene therapy lies in overcoming the safety and cargo constraints of viral vectors through advanced nanotechnology.

Fundamental principles of molecular biology, specifically the Central Dogma (DNA replication, transcription, and translation).
Basic concepts of recombinant DNA technology, including plasmids, promoters, enhancers, and gene cloning.
An introductory understanding of virology, particularly the structure of viruses and how they naturally infect host cells.
The foundational mechanism of CRISPR-Cas9 system, including guide RNA (gRNA) design and targeted double-strand breaks.
In-depth study of AAV capsid engineering and directed evolution to improve tissue-specific tropism and reduce immunogenicity.
The regulatory, ethical, and clinical trial frameworks required for translating gene therapy designs from laboratory research to human trials.
Comparative analysis of alternative gene delivery systems, such as lentiviral vectors and non-viral lipid nanoparticles (LNPs).
Advanced gene-editing modalities, including base editing, prime editing, and CRISPR-based epigenetic regulation (CRISPRa/CRISPRi).
24.6K views556likes16:53@APNAAMERICAOriginal Release: 2025-11-10

Gene therapy involves delivering functional genes to replace or correct defective genes causing disease; however, direct plasmid delivery faces challenges because cells naturally resist foreign genetic material, with only about 1% entering cells successfully. To overcome this, scientists utilize modified viruses as delivery vehicles—specifically adeno-associated virus (AAV)—which have been engineered to retain their natural ability to bind to and enter specific cell types while losing their capacity to multiply and cause disease. The AAV system requires three components: a plasmid containing the therapeutic gene of interest, a plasmid expressing viral rep and cap proteins needed for particle assembly, and a helper plasmid providing additional functions. When these are introduced into producer cells, they assemble into viral particles that can efficiently deliver genetic material to target tissues for therapeutic applications.